载脂蛋白E（Apo E）是一种主要由肝脏产生的糖基化分泌蛋白，其基因位于人类19号染色体，主要有E2、E3、E4 3种基因型，其中E3为野生型。Apo E携带脂质后与脂蛋白受体相结合，在清除血脂方面发挥着重要作用。研究表明，Apo E的异常与糖尿病的发生互为因果。Apo E数目的减少或基因多态性所致的蛋白结构变化均可通过血脂清除能力减弱引发糖尿病；而当机体患糖尿病后，高血糖、糖基化终末产物和低胰岛素等因素均可抑制细胞分泌Apo E。作者就Apo E与糖尿病关系的研究进展作一综述。

[1] MAHLEY R W.Apolipoprotein E:cholesterol transport protein with expanding role in cell biology[J].Science,1998,240(4852):622-630.
[2] RALL S C Jr,WEISGRABER K H,MAHLEY R W.Human apolipoprotein E.The complete amino acid sequence[J].J Biol Chem,1982,257(8):4171-4178.
[3] JAWIEN J,NASTALEK P,KORBUT R.Mouse models of experimental atherosclerosis[J].Physiol Pharmacol,2004,55(3):503-517.
[4] HUBACEK J A,ADAMKOVA V,SKODOVA Z.Rare variant of apolipoprotein E(Arg136→Ser)in two normolipidemic individuals[J].Physiol Res,2005,54(5):573-575.
[5] HAUSER P S,NARAYANASWAMI V,RYAN R O.Apolipoprotein E:from lipid transport to neurobiology[J].Prog Lipid Res,2011,50(1):62-74.
[6] SIEST G,PILLOT T,REGIS-BAILLY A,et al.Apolipoprotein E:an important gene and protein to follow in laboratory medicine[J].Clin Chem,1995,41(8 Pt 1):1068-1086.
[7] EIJI M,KAUZUKO K,MASAKO T,et al.Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis[J].Prog Lipid Res,2006,45(6):466-486.
[8] SEGALL M L,DHANASEKARAN P,BALDWIN F,et al.Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization[J].Lipid Res,2002,43(10):1688-1700.
[9] SEGREST J P,JONES M K,DELOOF H,et al.The amphipathic helix in the exchangeable apolipoproteins:a review of secondary structure and function[J].Lipid Res,1992,33(2):141-166.
[10] SCHELLENBERG G D,BOEHNKE M,WIJSMAN E M.Genetic association and linkage analysis of the apolipoprotein CII locus and familial Alzheimer's disease[J].Ann Neurol,1992,31(2):223-227.
[11] VERGES B.Lipid modification in type 2 diabetes:the role of LDL and HDL[J].Fundam Clin Pharmacol,2009,23(6):681-685.
[12] von ECKARDSTEIN A,SCHULTE H,ASSMANN G.Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study:implications for the definition of impaired fasting glucose by the American Diabetes Association.Prospective Cardiovascular Munster[J].Clin Endocrinol Metab,2000,85(9):3101-3108.
[13] KRAUS W E,HOUMARD J A,DUSCHA B D,et al.Effects of the amount and intensity of exercise on plasmalipoproteins[J].N Engl J Med,2002,347(19):1483-1492.
[14] RVTTI S,EHSES J A,SIBLER R A,et al.Low-and high-density lipoproteins modulate function,apoptosis,and proliferation of primary human and murine pancreatic β-cells[J].Endocrinology,2009,150(10):4521-4530.
[15] 庞翠军,肖常青,苏宏业.2 型糖尿病患者游离脂肪酸水平及其影响因素分析[J].广西医科大学学报,2009,26(5):711-713.
[16] LALAZAR A,WEISGRABER K H,RALL S C Jr,et al.Site-specific mutagenesis of human apolipoprotein E.Receptor binding activity of variants with single amino acid substitutions[J].Biol Chem,1988,263(8):3542-3545.
[17] GREGG R E,ZECH L A,SCHAEFER E J.Abnormal in vivo metabolism of apolipoprotein E4 in humans[J].Clin Invest,1986,78(3):815-821.
[18] WEISGRABER K H.Apolipoprotein E distribution among human plasma lipoproteins:role of the cysteine-arginine interchange at residue 112[J].Lipid Res,1990,31(8):1503-1511.
[19] ANIL E.The impact of EPA and DHA on blood lipids and lipoprotein metabolism:influence of apoE genotype[J].Proc Nutr Soc,2007,66(1):60-68.
[20] KAMRUECHA W,CHANSIRIKARNJANA S,NIMKULRAT E,et al.Rapid detection of apolipoprotein E genotypes in Alzheimer's disease using polymerase chain reaction-single strand conformation polymorphism[J].Southeast Asian J Trop Med Public Health,2006,37(4):793-797.
[21] TAVINT HARAN S,LIM S C,CHAN Y H,et al.Apolipoprotein E genotype affects the response to lipid lowering therapy in Chinese patients with type 2 diabetes mellitus[J].Diabetes Obes Metab,2007,9(1):81-86.
[22] MAITLAND van der Zee A H,JUKEMA J W,ZWINDERMAN A H,et al.Apolipoprotein E polymorphism and response to pravastatin in men with coronary artery disease(REGRESS)[J].Acta Cardiol,2006,61(3):327-331.
[23] HUMPHRIES S E,COOPER J A,TALMUD P J,et al.Candidate gene genotypes,along with conventional risk factor assessment,improve estimation of coronary heart disease risk in healthy UK men[J].Clin Chem,2007,53(1):8-16.
[24] FRIKKE-SCHMIDT R,SING C F,NORDESTGAARD B G,et al.Subsets of SNPs define rare genotype classes that predict ischemic heart disease[J].Hum Genet,2007,120(6):865-877.
[25] AKANJI A O,SURESH C G,FATANIA H R,et al.Associations of apolipoprotein E polymorphism with low-density lipoprotein size and subfraction profiles in Arab patients with coronary heart disease[J].Metabolism,2007,56(4):484-490.
[26] SEIP R L,OTVOS J,BILBIE C,et al.The effect of apolipoprotein E genotype on serum lipoprotein particle response to exercise[J].Atherosclerosis,2006,188(1):126-133.
[27] ANTHOPOULOS P G,HAMODRAKAS S J,BAGOS P G.Apolipoprotein E polymorphisms and type 2 diabetes:a meta-analysis of 30 studies including 5 423 cases and 8 197 controls[J].Mol Genet Metab,2010,100(3):283-291.
[28] 熊燏,周新,刘松梅.载脂蛋白E基因多态性与2 型糖尿病的关系[J].微循环学杂志,2008,18(2):28-29.
[29] ESPIRITU D J,HUANG Z H,ZHAO Y,et al.Hyperglycemia and advanced glycosylation end products suppress adipocyte apoE expression:implications for adipocyte triglyceride metabolism[J].Am J Physiol Endocrinol Metab,2010,299(4):E615-E623.
[30] BHATTACHARYYA S,DUDEJA P K,TOBACMAN J K.Carrageenan-induced NF-κB activation depends on distinct pathways mediated by reactive oxygen species and Hsp27 or by Bcl10[J].Biochim Biophys Acta,2008,1780(7-8):973-982.
[31] ESPIRITU D J,MAZZONE T.Oxidative stress regulates adipocyte apolipoprotein E and suppresses its expression in obesity[J].Diabetes,2008,57(11):2992-2998.
[32] YEOP HAN C,KARGI A Y,OMER M,et al.Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes:dissociation of adipocyte hypertrophy from inflammation[J].Diabetes,2010,59(2):386-396.
[33] LIN Y,BERG A H,IYANGAR P,et al.The hyperglycemia-induced inflammatory response in adipocytes:the role of reactive oxygen species[J].Biol Chem,2005,280(6):4617-4626.
[34] TAKAHASHI M,SUZUKI E,TAKEDA R,et al.Angiotensin II and tumor necrosis factor-alpha synergistically promote monocyte chemoattractant protein-1 expression:roles of NF-κB,p38,and reactive oxygen species[J].Am J Physiol Heart Circ Physiol,2008,294(6):H2879-H2888.
[35] CATHERINE M,LENICH A V,CHOBANIAN P B.Effect of dietary cholesterol and alloxan-diabetes on tissue cholesterol and apolipoprotein E mRNA levels in the rabbit[J].Lipid Res,1991,32(3):431-438.
[36] BACH-NGOHOU K,OUGUERRAM K,NAZIH H,et al.Apolipoprotein E kinetics:influence of insulin resistance and type 2 diabetes[J].Int J Obes Relat Metab Disord,2002,26(11):1451-1458.
[37] HOFMANN S M,PEREZ-TILVE D,GREER T M.Defective lipid delivery modulates glucose tolerance and metabolic response to diet in apolipoprotein E-deficient mice[J].Diabetes,2008,57(1):5-12.
[38] KAWASHIMA Y,CHEN J,SUN H.Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus[J].Diabetologia,2009,52(7):1434-1441.
[39] GAO J,KATAGIRI H,ISHIGAKI Y,et al.Involvement of apolipoprotein E in excess fat accumulation and insulin resistance[J].Diabetes,2007,56(1):24-33.
[40] SCHREYER S A,VICK C,LYSTIG T C.LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice[J].Am J Physiol Endocrinol Metab,2002,282(1):E207-E214.